Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

Summary

This is an open-label study enrolling healthy adults that participated in Study ARCT-021-01 (the Parent Study). Participants will receive either a single injection of ARCT-021 or no injection and be followed for up to 365 days.

Timeline

Start

2021-01-04

Primary completion

2021-12-28

Completion

2021-12-28

Outcome

Outcome not reported

Stopped (Business): “A decision was made to terminate the study for operational/business reasons. This study was not terminated for reasons of safety or immunogenicity.”

Drugs

Indications